Abstract:the advancement of radiotherapy in the past 50 years. Soon after the clinical introduction of computerized tomography (CT) it was employed in radiotherapy, in order to visualize internal organs and to calculate the volumes of the tumor target and internal organs close to the tumor which could be affected by the radiation dose (1). 3D imaging enabled the first studies of extracranial extreme hypofractionation, commonly called stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR). Timmerman et al pioneered SBRT in early stage lung cancer (2). The success of SABR for lung cancer was made possible by the ability to accurately identify the tumor on CT imaging of the thorax. Further incremental improvements came with realtime imaging on the radiotherapy (RT) treatment table (e.g cone beam CT) ensuring control and accurate delivery of SBRT plans.The application of SABR to mediastinal, abdominal and pelvic sites requires accurate and precise imaging of these areas as provided by magnetic resonance imaging (MRI). The first commercially available clinical MRI radiotherapy system began treating patients on a radioactive cobalt-based system in 2014 (3). Over the last 10 years there have been gradual developments in the delivery of MR guided RT, as the successful incorporation of Linac-based radiation into the ViewRay system and the development of rival machines such as the Elekta Unity. There are now over 100 installations of MR guided RT systems in the world. A PubMed search shows a steady increase in publications regarding MR Linac reaching over 200 per year in recent years. This volume is the second in a series of frontiers dedicated to advances in the clinical use of MR guided radiotherapy. The articles can be divided into 2 ovelapping broad categories, clinical experience and physics with quality assurance.A single institution series of pancreatic cancer patients receiving MRgSBRT to the pancreas with 5-10 Gy fractions shows the range of patients being treated today. The great majority have locally advanced inoperable disease. The series includes patients with locally recurrent disease following prior surgery or fractionated radiation and a few patients with oligo-progressive disease treated to both the primary and the oligometastasis. One of the difficulties of treating pancreatic tumors with MRgSBRT is the visualization of surrounding small bowel and real-time changes in organs at risk around the target tumor. Another paper reports on improved inter-observer contouring accuracy of pancreatic cancer MRI with the use of butylscopolamine prior to MRI.A major advantage of MRguided radiotherapy is the ability to have real time tumor tracking to ensure coverage of the target and avoid toxicity of adjacent organs. Two papers describe novel methods of tracking. A case report of a nodal recurrence of endometrial cancer used real time tracking of isodose lines to deliver daily isotoxic doses. A single institute series of intrathoracic tumors who received MRgSBRT due to proximity to organs at risk showed the importance of real time tracking. A further study looked at gating protocols for apical lung lesions. Cardiac lesions close to the right ventricles are especially difficult to treat with focal radiotherapy and in this series there is a report of 2 patients safely treated with a dose of 30 Gy in 3 fractions of 10 Gy each.A couple of papers described aspects in dosimetry of MR guided SBRT. One paper looked at techniques of delineation of gas packets and the impact of these gas packets using various dose and gas volume measurement protocols. Another paper reported on the benefits of online adaptation in the treatment of prostate cancer with MRgSBRT.The addition of non-proprietary software upgrades to MRgRT planning programs requires meticulous QA. An online QA program to evaluate such upgrades is described.In summary, the several papers in this volume describe a wide range of issues involved in implementing MRgSBRT and serve as an important addition to existing knowledge.

Upper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla Magnetic Resonance Imaging-Guided Linear Accelerator: Workflow and Physics Considerations

Initial clinical experience with using a 1.5 Tesla MR-Linac for stereotactic body radiotherapy for cancer of the upper abdomen

Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions

Adaptive hypofractionted and stereotactic body radiotherapy for lung tumors with real-time MRI guidance

Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation

Stereotactic Body Radiotherapy for Renal Cell Carcinoma—A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings

MR-guided stereotactic radiation therapy for head and neck cancers

Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy

Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide

Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma

Editorial: Radiation therapy using MRI-LINAC - the right way to start: a guide for physicians and physicists, volume II

Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios

Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results

Single-Isocenter, Multiple-Target Abdominal Cone-Beam Computed Tomography (CBCT)-Guided Online Adaptive Stereotactic Body Radiotherapy (SBRT)

CT-Guided Online Adaptive Radiotherapy Delivered via Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) for a Bulky Thoracic and Abdominal Mass in Oligometastatic Renal Cell Carcinoma

Dosimetric Evaluations of Different Accelerator Based Treatment Modalities for Curative Intent Stereotactic Body Radiation Therapy of Isolated Thoracic Spinal Metastases

Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors

Use of Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy for Oligometastatic Lung Adenocarcinoma: Leveraging CT-Guided Online Adaptive Radiotherapy

The Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Systematic Therapy for Metastatic Renal Cell Carcinoma: a Systematic Review and Meta‐analysis

Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors